Searched for
GSK PHARMA TARGET
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- GSK Pharma to expand into oncology, focus on adult vaccines in IndiaGlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and oncology in Indi...
- Kotak initiates coverage on Mankind Pharma, sees 11% upside. 3 reasons whyKotak Institutional Equities has initiated coverage on Mankind Pharma and given it an 'Add' rating with a target price of Rs 1,875. The bro...
- Motilal Oswal Financial Services neutral on GlaxoSmithKline; target price: Rs 1340GlaxoSmithKline Pharmaceuticals, incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 21043.62 Crore) operating...
- GlaxoSmithKline is saying goodbye to Bell Curve appraisalsHR experts feel over the years the traditional performance appraisal mechanism has outlived its utility, and a more robust system is needed.
- Reduce GSK Pharma, target Rs 2483: NomuraHowever, the market expects strong revival in EBITDA margins and the stock is factoring in possible delisting if parent Glaxo Plc buys back...
- GSK India to benefit from global business swap deal with NovartisGlaxo will get Novartis’ vaccine portfolio, including anti-rabies products such as Rabipur, while transferring its smaller oncology busines...
- Domestic pharma companies may gain as MNCs set to swallow bitter marketing pillA cautious strategy adopted by MNCs in promoting medicines could affect MNCs, including GSK, and impact their growth prospects in the India...
- GSK's open offer for buying stake in Indian arm from February 7-21GlaxoSmithKline Plc's Rs 6,389.02 crore open offer to pick up 24.33 per cent stake in its Indian arm GlaxoSmithKline Pharma will start from...
- GlaxoSmithKline Consumer Healthcare signs a brandsswap deal with GSK PharmaceuticalsThe cross-functional collaboration deal, to swap select brands and independently market, sell and distribute them, is one of the four lever...
- Brokerage views on DLF, Cummins India, Pharma and IT sectorRead on to know what brokerages have to say about select stocks that are likely to be in action today.
- Brokers' call on Tata Steel, Bharti Airtel and GSK PharmaMacquarie has downgraded the ratings of Tata Steel to ‘Underperform’ with a target price of Rs 306. Tata Steel, on a P/B adjusted for goodw...
- GSK not under compulsion to buy Indian companies: Hasit JoshipuraGSK will not pay exorbitant price to buy Indian companies as it is under no such compulsions, a top company executive said.
- Buy GSK Pharma: Ashwani GujralGSK Pharma which had a 5% move on Friday is now breaking out of its range that it had for about 2 to 3 months.
- Glaxosmithkline Pharma: Vaccine business to help maintain margin leadGlaxoSmithKline Pharma has grown across all its business segments and is on track to maintain its target of growing at close to 12-13 % ann...
- Promoters have no intention to reduce stake: Dr Reddy's MDPromoters of Dr Reddy's Laboratories have no intention of diluting their stake in the company, its managing director K Satish Reddy said to...
- ‘Productivity of global pharma R&D pipelines has fallen’The Indian arms of most global pharma giants have so far remained under-sized, rather off their parent’s radar for sometime now. But are th...
- Motilal Oswal maintains 'buy' on GSK PharmaMotilal Oswal Securities has maintained 'buy' on GlaxoSmithKline Pharmaceuticals for target price at Rs 1392.
- GSK enters JV for generics pushUK-based GSK on Thursday entered into an alliance with South African generic firm Aspen Pharma to sell the latter’s generic drugs in severa...
Load More
